Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange

A C M Figueira1, D M Saidemberg, P C T Souza

  • 1Universidade de São Paulo, Departamento Física e Informática, Instituto de Física, Avenida Trabalhador Sãocarlense 400, São Carlos, SP, Brazil.

Insights

Understanding thyroid hormone receptor (TR) structures is key for drug development. Ligands stabilize TRs, but the apo-TR structure and ligand-induced changes reveal allosteric communication and a novel model for TR conformational shifts.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Molecular Endocrinology

Background:

  • Thyroid hormone receptors (TRs) are crucial ligand-gated transcription factors regulating development and metabolism.
  • Existing structural data primarily focuses on agonist-bound TR ligand-binding domains (LBDs), with limited information on apo-TR or antagonist-bound states.

Purpose of the Study:

  • To elucidate the structural conformation of apo-TR LBD and its rearrangements upon ligand binding.
  • To investigate the allosteric mechanisms and conformational changes induced by agonists and antagonists.

Main Methods:

  • Hydrogen/deuterium exchange mass spectrometry (HDX-MS) was employed on TR LBDs with and without agonist (T3) or antagonist (NH3).
  • Proteolytic peptide analysis following HDX-MS identified regions of ligand-induced solvent protection.
  • Site-directed mutagenesis and molecular dynamics simulations were utilized to support the proposed structural model.

Main Results:

  • Both T3 and NH3 reduced deuterium incorporation, indicating tighter folding of the TR LBD.
  • Ligands protected regions near the binding pocket and the dimer interface (H10-H11), suggesting allosteric communication.
  • The C-terminal helix H12 remained protected in all states, while T3 specifically increased solvent accessibility in helices H3-H5.

Conclusions:

  • Ligand binding induces significant conformational changes in TR LBDs, extending beyond the immediate binding pocket.
  • A structural model is proposed where apo-TR H12 interacts with H3-H5, an interaction disrupted by T3 but not NH3.
  • These findings provide insights into TR structural dynamics crucial for developing targeted TR pharmaceuticals.

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...